MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway
- Leibo Wang
- Xuebin Zhang
- Jun Liu
- Qingjun Liu
Affiliations: Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin 300350, P.R. China, Department of Pathology, Tianjin Huanhu Hospital, Tianjin 300350, P.R. China
- Published online on: March 16, 2022 https://doi.org/10.3892/etm.2022.11260
Copyright: © Wang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Glioblastoma (GBM) is a malignant tumor with one of the fastest increasing morbidity and mortality rates. As such, more therapeutic targets need to be developed to combat this disease. Mucin 21 (MUC21) is a human counterpart of mouse epiglycanin and mediates multiple cellular functions. However, its possible effects on GBM and its possible mechanism remain unclear. The current study aimed to clarify the role or MUC21 in the progression of GBM by performing a series of in vitro assays, including Cell Counting Kit‑8, colony formation, wound closure, transwell, and in vivo assays. In the present study, the aberrantly high expression of MUC21 in human GBM tissues and cell lines was observed and it was revealed that it was associated with the clinicopathological feature, tumor recurrence, in patients with GBM. MUC21 promoted the viability and motility of GBM cells in vitro and stimulated tumor growth in vivo. It was further confirmed that MUC21 promoted the progression of GBM via the STAT3/AKT pathway and it was considered that MUC21 could serve as a promising target for the treatment of GBM.